New scan aims to spot brain cancer treatment effects sooner
NCT ID NCT07469735
Summary
This study is testing whether a new type of PET scan (called 18F-AGX PET) can detect early signs of how well the drug Vorasidenib is working in adults with a specific, recurring type of slow-growing brain tumor. The goal is to see if changes on this special scan happen before changes are visible on standard MRI scans, which could help doctors assess treatment response faster. Participants will take Vorasidenib daily for about a year and undergo both the new PET scans and regular MRI scans to compare results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital
Shanghai, Shanghai Municipality, 201100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.